Response to PD-1 blockade in a patient with mucosal melanoma of the middle ear: Case report

Hiroki Komatsuda1 | Takumi Kumai1,2 | Seigo Ueda1,3 | Yui Hirata-Nozaki1 | Tatsuya Hayashi2 | Yasuaki Harabuchi1

1Department of Otolaryngology-Head & Neck Surgery, Asahikawa Medical University, Asahikawa, Japan
2Department of Innovative Head & Neck Cancer Research and Treatment (IHNCRT), Asahikawa Medical University, Asahikawa, Japan
3Wakkanai E.N.T Clinic, Wakkanai, Japan

Correspondence
Takumi Kumai, Department of Otolaryngology-Head & Neck Surgery, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa 078-8510, Hokkaido, Japan. Email: t-kumai@asahikawa-med.ac.jp

Abstract
PD-1 blockade is a feasible approach in treating mucosal malignant melanomas of the middle ear.

Key words
middle ear, PD-1 blockade, primary mucosal melanoma

1 | INTRODUCTION

Primary mucosal malignant melanomas of the middle ear are rare, described in only a few case reports worldwide. We report a case of primary mucosal malignant melanoma of the middle ear treated with a PD-1 blockade. We present the case of an 80-year-old woman complaining of hearing difficulty in the right ear. A tumor extended from the right eardrum to the external auditory canal. A tumor biopsy revealed mucosal malignant melanoma. The patient was treated with nivolumab. The patient remained symptom-free for 60 months. PD-1 blockade is a feasible approach in treating mucosal malignant melanomas of the middle ear.

Primary mucosal malignant melanomas of the head and neck are relatively rare with most primary lesions generally found in the nasal cavity, paranasal sinuses, oral cavity, and pharyngeal mucosa. Primary mucosal malignant melanomas of the middle ear are extremely rare, described in only a few case reports worldwide.1-12 Since the outcomes of current treatment options for mucosal melanomas are poor, a novel approach is required to treat mucosal malignant melanomas of the middle ear. Immune checkpoint inhibitors have recently been reported to be effective in treating many types of cancer, especially cutaneous melanoma.13 The efficacy of immune checkpoint inhibitors for the treatment of mucosal melanomas, however, has not been fully evaluated. We report a case of primary mucosal malignant melanoma of the middle ear that was effectively treated with nivolumab, an anti-PD-1 antibody.

2 | CASE REPORT

An 80-year-old woman with a 2-year history of hearing difficulty was admitted to our hospital after her primary care physician found edema of the right eardrum. Edema with active bleeding was visualized from the right eardrum to the external auditory canal (Figure 1). Computed
tomography (CT) and magnetic resonance imaging (MRI) revealed a tumor that extended from the middle ear cavity to the external auditory canal (Figure 2). A fluorodeoxyglucose-positron emission tomography (FDG-PET) scan revealed FDG accumulation that was limited to the ear. A biopsy of the tumor revealed a mass that was comprised of melatonin-containing large cells, confirming the diagnosis of malignant melanoma (stage T4 on the Pittsburgh staging system). Since the tumor expressed high levels of PD-L1, the patient was treated with nivolumab (Figure 3). Three mg/kg of nivolumab was administered every 2 weeks. Reduction in tumor size was noticed immediately after treatment was begun (Figure 4). After treatment began, the patient was examined once a month and had a MRI scan every 3 months. After eight courses of treatment, the tumor was limited to the middle ear cavity and stopped bleeding (Figure 5). The patient has remained stable for more than 60 months after her first visit without serious adverse events or progression of symptoms.

3 | DISCUSSION

The incidence rate of malignant melanomas is 1-2 per 100 000 in Japan, among which primary mucosal melanomas account for only a few percent. Mucosal melanoma has an aggressive prognosis because of the high rate of local recurrence and distant metastasis. The overall 5-year survival rate is no more than 30%. The treatment of malignant melanoma is surgical resection of the primary site with appropriately wide margins. However, for melanoma of the head and neck, function-preserving resection is difficult. The effect of chemotherapy and radiation therapy on mucosal melanoma remains unknown. Recently, several reports have suggested that a PD-1 inhibitor alone or in combination with a CTLA-4 inhibitor is effective in treating melanoma. However, there are few reports of the use of these immune checkpoint inhibitors in mucosal melanoma.

Of primary malignant melanomas, a tumor originating in the middle ear is rare with only 12 reports to date. Early manifestations of this tumor are hearing difficulty and otorrhea. Most are misdiagnosed as serous otitis media. The treatment outcome is poor, even with extended surgical removal, and the longest survival period documented in past reports was approximately 24 months. Since our tumor was positive for PD-L1 expression, the patient was successfully treated with nivolumab, an anti-PD-1 antibody.

Although direct evidence is obscure, the blockade of immune checkpoints could be a promising approach in treating primary malignant mucosal melanomas of the middle ear.

4 | CONCLUSION

We report a case of primary mucosal malignant melanoma of the middle ear treated with a PD-1 blockade. PD-1 blockade is a feasible approach in treating mucosal malignant melanomas of the middle ear.
ACKNOWLEDGMENT
This work was supported by JSPS KAKENHI Grant Number 16K20223.
Written informed consent was obtained from the patient for publication of this case report and accompanying images.

CONFLICT OF INTEREST
None declared.

AUTHOR CONTRIBUTIONS
HK and KT: contributed to acquisition of data, drafting the manuscript, final revision of the manuscript, and participated sufficiently in the work. SU, YH, TH, and YH: contributed to acquisition of data, drafting the manuscript, and participated sufficiently in the work.

ORCID
Hiroki Komatsuda https://orcid.org/0000-0002-3783-2746
Takumi Kumai https://orcid.org/0000-0002-3411-671X

REFERENCES
1. McKenna EL Jr, Holmes WF, Harwick R. Primary melanoma of the middle ear. Laryngoscope. 1984;94(11 Pt 1):1459-1460.
2. Sherman IW, Swift AC, Haqqani MT. Primary mucosal malignant melanoma of the middle ear. J Laryngol Otol. 1991;105(12):1061-1064.
3. Banerjee A, Meikle D. Malignant melanoma of the middle ear. J Laryngol Otol. 1992;106(6):581.
4. Urpegui Garcia A, Lahoz Zamarro T, Muniesa Soriano JA, et al. Malignant melanoma of the middle ear, a rare site. Acta Otorrinolaringol Esp. 1999;50(7):559-562.
5. Uchida M, Matsunami T. Malignant amelanotic melanoma of the middle ear. Arch Otolaryngol Head Neck Surg. 2001;127(9):1126-1128.
6. Ozturk O, Baglam T, Uneri C, Kullu S. Primary malignant melanoma of the middle ear mucosa: a case report. Kulak Burun Bogaz Ihtis Derg. 2006;16(2):83-86.
7. Mehta BS, Maniyar H. Primary mucosal malignant melanoma of middle ear - A case report. Indian J Otolaryngol Head Neck Surg. 2007;59(1):71-72.

FIGURE 3 The pathological finding of tumor. A, Hematoxylin and eosin staining, original magnification ×200. B, The tumor cells were positive for PD-L1. (PD-L1 SP142 staining, original magnification ×200)

FIGURE 4 The tumor image after eight courses of nivolumab. The eardrum was visible, and the tumor was limited to the middle ear cavity

FIGURE 5 T1-weighted axial MRI after eight courses of nivolumab. The tumor was limited to the middle ear cavity
8. Curry JM, Kung BC, Willcox TO Jr. Malignant melanoma of the middle ear. *Otolaryngol Head Neck Surg*. 2007;136(5):856-857.
9. Luo H, Liang JJ, Jiang Y. Primary malignant melanoma of the middle ear and mastoid: a case report. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi*. 2008;43(11):865-866.
10. Huellner MW, Cousin M, Linder T, et al. Melanoma of the middle ear: initial presentation, Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging and follow up. *J Laryngol Otol*. 2011;125(5):536-539.
11. Peters G, Arriaga MA, Nuss DW, Pou AM, DiLeo M, Scantz K. Mucosal melanoma of the middle ear cavity and Eustachian tube: a case report, literature review, and focus on surgical technique. *Otol Neurotol*. 2012;33(2):239-243.
12. Maxwell AK, Takeda H, Gubbels SP. Primary middle ear mucosal melanoma: case report and comprehensive literature review of 21 cases of primary middle ear and Eustachian tube melanoma. *Ann Otol Rhinol Laryngol*. 2018;127(11):856-863.
13. Shoushtari AN, Munhoz RR, Kuk D, et al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. *Cancer*. 2016;122(21):3354-3362.
14. Tas F, Keskin S, Karadeniz A, et al. Noncutaneous melanoma have distinct features from each other and cutaneous melanoma. *Oncology*. 2011;81:353-358.
15. Iddings DM, Fleisig AJ, Chen SL, Faries MB, Morton DL. Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients? *Ann Surg Oncol*. 2010;17:40-44.
16. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*. 2010;363(8):711-723.
17. Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. *Lancet Oncol*. 2018;19(11):1480-1492.

**How to cite this article:** Komatsuda H, Kumai T, Ueda S, Hirata-Nozaki Y, Hayashi T, Harabuchi Y. Response to PD-1 blockade in a patient with mucosal melanoma of the middle ear: Case report. *Clin Case Rep*. 2020;8:3467–3470. [https://doi.org/10.1002/ccr3.3424](https://doi.org/10.1002/ccr3.3424)